Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours

被引：1
|
作者：
Rodon, J. [1 ]
Peltola, K. [2 ]
Azaro, A. [1 ]
Alvarez, E. Castanon [3 ]
Garratt, C. [4 ]
Leskinen, H. [5 ]
Bjorklund, H. [6 ]
Ruck, A. [4 ]
Massard, C. [3 ]
Bono, P. [2 ]
机构：
[1] Vall dHebron Univ Hosp, Med Oncol, Inst Oncol, Barcelona, Spain
[2] Univ Helsinki, Cent Hosp, Comprehens Canc Ctr, Helsinki, Finland
[3] Inst Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France
[4] Orion Pharma, Oncol & Crit Care, Nottingham, England
[5] Orion Pharma, Drug Safety, Helsinki, Finland
[6] Orion Pharma, Drug Metab, Turku, Finland
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw368.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
    Bono, P.
    Massard, C.
    Peltola, K.
    Azaro, A.
    Italiano, A.
    Kristeleit, R. S.
    Lassen, U. N.
    Arkenau, H-T.
    Hakulinen, P.
    Garratt, C.
    Ikonen, T.
    Mustonen, M.
    Rodon, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours.
    Ahnert, Jordi Rodon
    Garratt, Chris
    Laapas, Kaisa
    Leskinen, Hanna
    Bjorklund, Harry
    Ruck, Angela
    Peltola, Katriina
    Azaro, Analia
    Castanon-Alvarez, Eduardo
    Massard, Christophe
    Bono, Petri
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
    Holmstrom, Tim H.
    Moilanen, Anu-Maarit
    Ikonen, Tarja
    Bjorkman, Mari L.
    Linnanen, Tero
    Wohlfahrt, Gerd
    Karlsson, Stefan
    Oksala, Riikka
    Korjamo, Timo
    Samajdar, Susanta
    Rajagopalan, Srinivasan
    Chelur, Shekar
    Narayanan, Kishore
    Ramachandra, Raghuveer K.
    Mani, Jiju
    Nair, Rashmi
    Gowda, Nagaraj
    Anthony, Thomas
    Dhodheri, Samiulla
    Mukherjee, Subhendu
    Ujjinamatada, Ravi K.
    Srinivas, Nanduri
    Ramachandra, Murali
    Kallio, Pekka J.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (01) : 28 - 38
  • [4] ODM-203, a novel, selective and balanced FGFR and VEGFR inhibitor with strong anti-tumor activity in FGFR- and VEGFR-dependent cancer models
    Holmstrom, T.
    Moilanen, A.
    Linnanen, T.
    Wohlfahrt, G.
    Karlsson, S.
    Oksala, R.
    Korjamo, T.
    Bjorkman, M.
    Samajadar, S.
    Rajagopalan, S.
    Chelur, S.
    Narayan, K.
    Ramachandra, R.
    Anthony, T.
    Ds, S.
    Ramachandra, M.
    Kallio, P.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 142 - 142
  • [5] ODM-203, a novel, selective and balanced FGFR and VEGFR inhibitor with strong activity on primary and metastatic tumor growth in FGFR-dependent and angiogenic cancer models
    Holmstrom, Tim
    Moilanen, Anu
    Bjorkman, Mari
    Linnanen, Tero
    Wohlfahrt, Gerd
    Karlsson, Stefan
    Oksala, Riikka
    Korjamo, Timo
    Samajdar, Susanta
    Rajagopalan, Srinivasan
    Chelur, Shekar
    Narayan, Kishore
    Ramachandra, Raghuveer
    Anthony, Thomas
    Samiulla, D. S.
    Ramachandra, Murali
    Kallio, Pekka
    CANCER RESEARCH, 2015, 75
  • [6] Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours
    Bono, Petri
    Massard, Christophe
    Peltola, Katriina J.
    Azaro, Analia
    Italiano, Antoine
    Kristeleit, Rebecca S.
    Curigliano, Giuseppe
    Lassen, Ulrik
    Arkenau, Hendrik-Tobias
    Hakulinen, Pasi
    Garratt, Chris
    Ikonen, Tarja
    Mustonen, Mika V. J.
    Rodon, Jordi A.
    ESMO OPEN, 2020, 5 (06)
  • [7] Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors
    Xu, J.
    Wang, Y.
    Ye, C. Y.
    Huang, C.
    Zhang, X. H.
    Sai, Y.
    Shen, L.
    Mu, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Shen, Lin
    Gong, Jifang
    Huang, Cheng
    Ye, Chen Yang
    Yang, Li
    Sai, Yang
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
    Papadopoulos, K. P.
    El-Rayes, B. F.
    Tolcher, A. W.
    Patnaik, A.
    Rasco, D. W.
    Harvey, R. D.
    LoRusso, P. M.
    Sachdev, J. C.
    Abbadessa, G.
    Savage, R. E.
    Hall, T.
    Schwartz, B.
    Wang, Y.
    Kazakin, J.
    Shaib, W. L.
    BRITISH JOURNAL OF CANCER, 2017, 117 (11) : 1592 - 1599
  • [10] A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
    K P Papadopoulos
    B F El-Rayes
    A W Tolcher
    A Patnaik
    D W Rasco
    R D Harvey
    P M LoRusso
    J C Sachdev
    G Abbadessa
    R E Savage
    T Hall
    B Schwartz
    Y Wang
    J Kazakin
    W L Shaib
    British Journal of Cancer, 2017, 117 : 1592 - 1599
12345